	2019 LABORATORT TES	STING PRACTICES FOR CANDIDER	VIIA QUESTIONI	IAINE
1\	What kind of laboratory is this facility	(2 (calact and)		
1)	What kind of laboratory is this facility Hospital laboratory		thor (specify)	
	Commercial laboratory (Quest, et		Inknown	
21		,		cara facilities?
2)	Does this facility ever receive blood c		other long term	Unknown
۵۱		∐ No	omenata Navaslas	
3)	Does the clinical microbiology laborate	· <u>-</u>	eparate iviycolog	·
۵١	☐ Yes	∐ No		Unknown
4)	What kind of blood culture system do			
	☐ BacT/Alert	<u>=</u>	actec FX	
	☐ BacT/Alert 3D		solator tubes	
		LJ 0	ther (specify)	
	Bactec 9240			
5)	What is the approximate volume of $\underline{\underline{a}}$	•	rmed <u>annually</u> ii	n your laboratory?
	Specify number:	Unknown		
6)	What is the approximate volume of f	_	rmed <u>annually</u> ii	n your laboratory?
	Specify number:	JUnknown		
7) How does your lab identify yeast? (check all that apply)		
	MALDI-TOF Bruker (Biotyper)	····-	actiCard Candida	3
	MALDI-TOF bioMerieux (VITEK M		D Phoenix	
	VITEK 2	_	1icroScan	
	API 20C		apID Plus	
			•	
	DNA sequencing			
	PNA-FISH		Inknown	
۵۱	Door vor laborator vortinal voc		differentiation	o of Complide includes
8)	Does your laboratory routinely use Cl		or differentiation	
	Yes	∐ No		Unknown
9)	Species-level identification is perform	ned for <i>Candida</i> spp. isolated fro	m which of the	following?
	a. Blood isolates			
	Yes, reflexively	Yes, with clinician order	□No	Unknown
	<u> </u>			
	b. Other normally sterile body			
	Yes, reflexively	Yes, with clinician order	∐ No	Unknown
	c. Abdominal isolates			
	Yes, reflexively	Yes, with clinician order	No	Unknown
	_			_
	d. Respiratory isolates		—	
	Yes, reflexively	Yes, with clinician order	∐ No	Unknown
	e. Urine isolates			
	Yes, reflexively	Yes, with clinician order	□No	Unknown
	-		_	
	f. Other (specify)		□.	
	Yes, reflexively	Yes, with clinician order	No	Unknown

Public reporting burden of this collection of information is estimated to average 20 minutes for the entire survey, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB Control Number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Request Office, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA (0920-0978).

Lab ID No. [][][][][]

a. If Yes, when did this lab first start using T2Candida Panel?			No (go to 11)	Unknown
Yes, reflexively No Yes, with a clinical order Unknown oes your laboratory employ the BioFire (FilmArray) to identify Candida from blood culture? Yes (go to 11a) No (go to 12) unknown a. If Yes, when did this lab first start using BioFire? Date (mm/dd/yyyy):/	b.	If Yes, when did this lab first s	tart using T2Candida Panel? Da	te (mm/dd/yyyy):/
Yes (go to 11a)		Yes, reflexively	□ No	
b. If Yes, does this lab reflexively culture blood if you get a positive result on BioFire? Yes, reflexively Yes, with a clinical order No for both Question 10 and 11, does your laboratory have plans to employ culture-independent iagnostics for Candida identification in the near future (e.g. T2Candida Panel, BioFire)? Yes Unknown No Not applicable (Yes to Q17 or Q18) Des your laboratory offer any antifungal susceptibility testing for Candida? Yes (Continue onto Page 2) No (If No, QUESTIONNAIRE COMPLETE)	_		_	_
Yes, reflexively Yes, with a clinical order No for both Question 10 and 11, does your laboratory have plans to employ culture-independent lagnostics for Candida identification in the near future (e.g. T2Candida Panel, BioFire)? Yes Unknown No No Not applicable (Yes to Q17 or Q18) Pees your laboratory offer any antifungal susceptibility testing for Candida? Yes (Continue onto Page 2) No (If No, QUESTIONNAIRE COMPLETE)	a.	If Yes, when did this lab first s	tart using BioFire? Date (mm/do	d/yyyy):/
agnostics for Candida identification in the near future (e.g. T2Candida Panel, BioFire)? Yes No Not applicable (Yes to Q17 or Q18) es your laboratory offer any antifungal susceptibility testing for Candida? Yes (Continue onto Page 2) No (If No, QUESTIONNAIRE COMPLETE)	b.	Yes, reflexively	□ No)
Yes Unknown No Not applicable (Yes to Q17 or Q18) Sees your laboratory offer any antifungal susceptibility testing for Candida? Yes (Continue onto Page 2) No (If No, QUESTIONNAIRE COMPLETE)			•	
pes your laboratory offer any antifungal susceptibility testing for <i>Candida</i> ? Yes (<i>Continue onto Page 2</i>) No (<i>If No, QUESTIONNAIRE COMPLETE</i>)	agiio		_	· · · · · · · · · · · · · · · · · · ·
Yes (Continue onto Page 2) No (If No, QUESTIONNAIRE COMPLETE)		No	☐ No	et applicable (Yes to Q17 or Q18)

2019 Page **2** of **4**

Where is antifungal susceptibility testing (AFST) done On-site, in the laboratory	er (check all that apply)
Sent to commercial lab	
Sent to affiliated hospital lab	
Other	
Unknown	
OTKHOWIT	
i) Is antifungal susceptibility testing available for any o	f the following antifungal drugs (check all that apply):
Fluconazole	Caspofungin
Voriconazole	Amphotericin B
Itraconazole	
	☐ Flucytosine
Posaconazole	Uther (specify)
☐ Micafungin	Unknown
Anidulafungin	
s) What methods are used for AFST? (check all that app	alv)
Non-commercial broth microdilution	Vitek
☐ YeastOne	Other
☐ E test	Unknown
<u> </u>	
a. If you use Vitek for AFST, what <i>Candida</i> spec	
C. albicans	C. parapsilosis
C. glabrata	Other <i>Candida</i> spp.
') How are results of AFST reported? (select one)	
Categorical interpretation only (susceptible,	Bothcategorical interpretation PLUS MIC
resistant, etc.)	Unknown
MIC only	слинемп
a. If categorical interpretation only, how do yo	ou determine the categorical interpretation? (check all th
apply)	
CLSI M27 S4	Apply epidemiologic breakpoints
CLSI M27 S3	Other
From manufacturer of MIC test	
B) For what type of <i>Candida</i> isolates is antifungal suscep	ptibility testing (AFST) performed
automatically/reflexively? (check all that apply)	——————————————————————————————————————
Blood isolates	No AFST performed automatically (require
Other normally sterile body site isolates	order from a clinician)
Other (specify)	Unknown

2019 Page **3** of **4**

Lab ID No. [][][][][]

Page **4** of **4**

a.	C. albicans	lovivoly (Co to 100i)					
	Performed automatically/reflexively (Go to 19ai) Performed with a clinician's order						
	Not performed	order					
	Not performed						
	i. Drugs for which AFST is performed automatically/reflexively on <i>C. abicans</i> (check all that apply):						
	☐ Micafungin	Fluconazole	Other				
	Anidulafungin	Voriconazole	Unknown				
	Caspofungin	Amphotericin B					
b.	C. glabrata						
	Performed automatically/ref	lexively (Go to 19bi)					
	Performed with a clinician's						
	Not performed	3.46.					
	Not performed						
	_ •	·	y on <i>C. glabrata</i> (check all that appl				
	Micafungin	Fluconazole	U Other				
	Anidulafungin	Voriconazole	Unknown				
	Caspofungin	Amphotericin B					
c.	C. parapsilosis						
	Performed automatically/ref	lexively (Go to 19ci)					
	Performed with a clinician's						
	Not performed	3.46.					
							
	i. Drugs for which AFST is apply):	performed automatically/reflexive	y on <i>C. parapsilosis</i> (check all that				
	Micafungin	Fluconazole	Other				
	= ~	Voriconazole					
	Anidulafungin	<u>=</u>	Unknown				
	Caspofungin	Amphotericin B					
d.	Other Candida spp.						
	Performed automatically/reflexively (Go to 19di)						
	Performed with a clinician's order						
	☐ Not performed						
	i. Drugs for which AFST is performed automatically/reflexively on other Candida spp. (check all tha						
	apply):						
	Micafungin	Fluconazole	U Other				
	Anidulafungin	Voriconazole	Unknown				
	Caspofungin	Amphotericin B					
		END OF QUESTIONNAIRE					

2019